Importantly, we showed that WNT6 and HOXA9 are prognostically valuable, independently of each other, in GBM patients, and that their concomitant high expression identifies a subgroup of patients with very dismal prognosis (Table 2, Figs 7 and S7). The gene discussed is HOXA9; the disease is glioblastoma.